Dunad Therapeutics Overview

  • Year Founded
  • 2020

Year Founded

  • Status
  • Private

  • Employees
  • 12

Employees

  • Latest Deal Type
  • Early Stage VC

  • Latest Deal Amount
  • $24.1M

  • Investors
  • 7

Dunad Therapeutics General Information

Description

Developer of a proprietary tunable covalent chemistry platform designed to discover and develop medicines that selectively and durably target disease drivers. The company combines a deep understanding of disease biology with advanced chemistry to modulate protein stability and conformation, enabling pharmaceutical companies to create targeted therapies.

Contact Information

Website
www.dunadtx.com
Formerly Known As
Warhead
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • The Officers Mess
  • Royston Road
  • Cambridge CB22 4QH
  • England, United Kingdom
+44
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Corporate Office
  • The Officers Mess
  • Royston Road
  • Cambridge CB22 4QH
  • England, United Kingdom
+44

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Dunad Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
4. Early Stage VC 02-Nov-2021 $24.1M Completed Pre-Clinical Trials
3. Early Stage VC (Series A) 24-Mar-2021 Completed Pre-Clinical Trials
2. Accelerator/Incubator 01-Feb-2020 Completed Pre-Clinical Trials
1. University Spin-Out 01-Jan-2020 Completed Startup
To view Dunad Therapeutics’s complete valuation and funding history, request access »

Dunad Therapeutics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Ordinary 2
Series A 1,000,000 $0.001369 $6.85 $6.85 $6.85 56.94%
To view Dunad Therapeutics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Dunad Therapeutics Patents

Dunad Therapeutics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026136220-A1 Combination therapies with pikfyve kinase inhibitors Pending 16-Dec-2024
WO-2026136219-A1 Pikfyve assay Pending 16-Dec-2024
US-20260274825-A1 Pikfyve kinase inhibitors Pending 16-Dec-2024
WO-2026136226-A1 Pikfyve kinase inhibitors Pending 16-Dec-2024
WO-2026136228-A1 Pikfyve kinase inhibitors Pending 16-Dec-2024 C07D403/14
To view Dunad Therapeutics’s complete patent history, request access »

Dunad Therapeutics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Dunad Therapeutics Investors (7)

Investor Name Investor Type Holding Investor Since Participating Rounds
Alpha Wave Global Growth/Expansion Minority
BioGeneration Ventures Venture Capital Minority
Novartis Corporation Minority
Wellington Partners Venture Capital Minority
Epidarex Capital Venture Capital Minority
You’re viewing 5 of 7 investors. Get the full list »

Dunad Therapeutics FAQs

  • When was Dunad Therapeutics founded?

    Dunad Therapeutics was founded in 2020.

  • Where is Dunad Therapeutics headquartered?

    Dunad Therapeutics is headquartered in Cambridge, United Kingdom.

  • What is the size of Dunad Therapeutics?

    Dunad Therapeutics has 12 total employees.

  • What industry is Dunad Therapeutics in?

    Dunad Therapeutics’s primary industry is Drug Discovery.

  • Is Dunad Therapeutics a private or public company?

    Dunad Therapeutics is a Private company.

  • What is the current valuation of Dunad Therapeutics?

    The current valuation of Dunad Therapeutics is .

  • What is Dunad Therapeutics’s current revenue?

    The current revenue for Dunad Therapeutics is .

  • How much funding has Dunad Therapeutics raised over time?

    Dunad Therapeutics has raised $31.1M.

  • Who are Dunad Therapeutics’s investors?

    Alpha Wave Global, BioGeneration Ventures, Novartis, Wellington Partners, and Epidarex Capital are 5 of 7 investors who have invested in Dunad Therapeutics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process